LINK . SPRINGER . COM {}

Matching Content Categories {📚}

• Science
• Health & Fitness
• Non-Profit & Charity

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

patients, ipilimumab, nivolumab, combination, therapy, pubmed, article, trials, checkpoint, google, scholar, melanoma, immunotherapy, cancer, treatment, trial, response, cas, tumor, inhibition, pdl, nct, cell, combined, ctla, mgkg, cells, clinical, monotherapy, phase, checkmate, adverse, events, nsclc, months, pembrolizumab, central, study, immune, weeks, outcomes, advanced, regimens, antictla, pdpdl, data, objective, receiving, survival, regimen,

Topics {✒️}

/press-release/bristolmyers/bristol-myers-squibb-announces-top-line-resultscheckmate-026-phase-3-stu /oncology-times/blog/fdaactionsandupdates/pages/post braf-v600 kinase inhibitor anti-pd-1/pd-l1 moab braf-mutant unresectable/metastatic melanoma pd-1/pd-l1 checkpoint inhibitors anti-ctla-4 immune-checkpoint inhibitor targeting pd-1/pd-l1 interactions anti–pd-1/pd-l1 therapy anti-ctla-4 immune-checkpoint inhibitors anti-tumor t-cell activity pd-1/pd-l1 blockade immunotherapy pan-raf kinase inhibitor /science/article/pii/s1044579x0700034x pd-1/pd-l1 mediated induction anti-lpam-1/α4β7 moab low-dose combination therapy igg4 anti-pd-1 moab anti-pd-l1 moab dual-immune checkpoint inhibition immune-checkpoint inhibitors targeting anticancer monoclonal antibodies pd-1/pd-l1 inhibition pd-l1 mediates peripheral small-cell lung cancer small-cell lung cancer immune-related adverse events anti-pd-1/pd-l1 recurrent squamous-cell carcinoma pd-1/pd-l1 inhibitors igg2 anti-ctla-4 moab programmed death receptor-1 treatment-related adverse events raf kinase inhibitor major histocompatibility complex advancing anti-cancer immunotherapy anti-ctla-4 checkpoint inhibitors single-agent immunotherapy regimens approved monoclonal antibodies tumor pd-l1 status braf protein inhibitor programmed cell death high pd-l1 expression patient-reported outcomes version carboplatin 6 mg/ml/min carboplatin 5 mg/ml/min braf-wild type melanoma tumor pd-l1 expression pd-l1 negative melanoma compare single-agent immunotherapy

Questions {❓}

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
         description:Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes with immunotherapy agents have led to the formulation of advanced treatment strategies. Recent evidence from pre-clinical studies evaluating immune-checkpoint inhibitors in various cancer cell-lines has suggested that combinatorial approaches may have superior survival outcomes compared to single-agent immunotherapy regimens. Preliminary trials assessing combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 immune-checkpoint inhibitors have documented considerable advantages in survival indices over single-agent immunotherapy. The therapeutic potential of combinatorial approaches is highlighted by the recent FDA approval of nivolumab plus ipilimumab for patients with advanced melanoma. Presently, dual-immune checkpoint inhibition with anti-programmed death receptor-1/programmed cell death receptor- ligand-1 (anti-PD-1/PD-L1) plus anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) monoclonal antibodies (MoAbs) is being evaluated for a wide range of tumor histologies. Furthermore, several ongoing clinical trials are investigating combination checkpoint inhibition in association with traditional treatment modalities such as chemotherapy, surgery, and radiation. In this review, we summarize the current landscape of combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 MoAbs for patients with melanoma and non-small cell lung cancer (NSCLC). We present a synopsis of the prospects for expanding the indications of dual immune-checkpoint inhibition therapy to a more diverse set of tumor histologies.
         datePublished:2018-05-16T00:00:00Z
         dateModified:2018-05-16T00:00:00Z
         pageStart:1
         pageEnd:27
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s40425-018-0349-3
         keywords:
            Non-small Cell Lung Cancer (NSCLC)
            Checkpoint Inhibitor Combination
            Single-agent Immunotherapy
            Ipilimumab Combination Therapy
            Recommended Phase 2 Dose (RP2D)
            Oncology
            Immunology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-018-0349-3/MediaObjects/40425_2018_349_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-018-0349-3/MediaObjects/40425_2018_349_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-018-0349-3/MediaObjects/40425_2018_349_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-018-0349-3/MediaObjects/40425_2018_349_Fig4_HTML.gif
         isPartOf:
            name:Journal for ImmunoTherapy of Cancer
            issn:
               2051-1426
            volumeNumber:6
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Young Kwang Chae
               affiliation:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                     address:
                        name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                        type:PostalAddress
                     type:Organization
                     name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
                     address:
                        name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
                        type:PostalAddress
                     type:Organization
                     name:Northwestern University Feinberg School of Medicine
                     address:
                        name:Northwestern University Feinberg School of Medicine, Chicago, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Ayush Arya
               affiliation:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                     address:
                        name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Wade Iams
               affiliation:
                     name:Northwestern University Feinberg School of Medicine
                     address:
                        name:Northwestern University Feinberg School of Medicine, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marcelo R. Cruz
               affiliation:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                     address:
                        name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sunandana Chandra
               affiliation:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                     address:
                        name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                        type:PostalAddress
                     type:Organization
                     name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
                     address:
                        name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
                        type:PostalAddress
                     type:Organization
                     name:Northwestern University Feinberg School of Medicine
                     address:
                        name:Northwestern University Feinberg School of Medicine, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jaehyuk Choi
               affiliation:
                     name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
                     address:
                        name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
                        type:PostalAddress
                     type:Organization
                     name:Northwestern University Feinberg School of Medicine
                     address:
                        name:Northwestern University Feinberg School of Medicine, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Francis Giles
               affiliation:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                     address:
                        name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                        type:PostalAddress
                     type:Organization
                     name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
                     address:
                        name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
                        type:PostalAddress
                     type:Organization
                     name:Northwestern University Feinberg School of Medicine
                     address:
                        name:Northwestern University Feinberg School of Medicine, Chicago, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
      description:Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes with immunotherapy agents have led to the formulation of advanced treatment strategies. Recent evidence from pre-clinical studies evaluating immune-checkpoint inhibitors in various cancer cell-lines has suggested that combinatorial approaches may have superior survival outcomes compared to single-agent immunotherapy regimens. Preliminary trials assessing combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 immune-checkpoint inhibitors have documented considerable advantages in survival indices over single-agent immunotherapy. The therapeutic potential of combinatorial approaches is highlighted by the recent FDA approval of nivolumab plus ipilimumab for patients with advanced melanoma. Presently, dual-immune checkpoint inhibition with anti-programmed death receptor-1/programmed cell death receptor- ligand-1 (anti-PD-1/PD-L1) plus anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) monoclonal antibodies (MoAbs) is being evaluated for a wide range of tumor histologies. Furthermore, several ongoing clinical trials are investigating combination checkpoint inhibition in association with traditional treatment modalities such as chemotherapy, surgery, and radiation. In this review, we summarize the current landscape of combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 MoAbs for patients with melanoma and non-small cell lung cancer (NSCLC). We present a synopsis of the prospects for expanding the indications of dual immune-checkpoint inhibition therapy to a more diverse set of tumor histologies.
      datePublished:2018-05-16T00:00:00Z
      dateModified:2018-05-16T00:00:00Z
      pageStart:1
      pageEnd:27
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s40425-018-0349-3
      keywords:
         Non-small Cell Lung Cancer (NSCLC)
         Checkpoint Inhibitor Combination
         Single-agent Immunotherapy
         Ipilimumab Combination Therapy
         Recommended Phase 2 Dose (RP2D)
         Oncology
         Immunology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-018-0349-3/MediaObjects/40425_2018_349_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-018-0349-3/MediaObjects/40425_2018_349_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-018-0349-3/MediaObjects/40425_2018_349_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs40425-018-0349-3/MediaObjects/40425_2018_349_Fig4_HTML.gif
      isPartOf:
         name:Journal for ImmunoTherapy of Cancer
         issn:
            2051-1426
         volumeNumber:6
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Young Kwang Chae
            affiliation:
                  name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                  address:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                     type:PostalAddress
                  type:Organization
                  name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
                  address:
                     name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
                     type:PostalAddress
                  type:Organization
                  name:Northwestern University Feinberg School of Medicine
                  address:
                     name:Northwestern University Feinberg School of Medicine, Chicago, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Ayush Arya
            affiliation:
                  name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                  address:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Wade Iams
            affiliation:
                  name:Northwestern University Feinberg School of Medicine
                  address:
                     name:Northwestern University Feinberg School of Medicine, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marcelo R. Cruz
            affiliation:
                  name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                  address:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sunandana Chandra
            affiliation:
                  name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                  address:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                     type:PostalAddress
                  type:Organization
                  name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
                  address:
                     name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
                     type:PostalAddress
                  type:Organization
                  name:Northwestern University Feinberg School of Medicine
                  address:
                     name:Northwestern University Feinberg School of Medicine, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jaehyuk Choi
            affiliation:
                  name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
                  address:
                     name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
                     type:PostalAddress
                  type:Organization
                  name:Northwestern University Feinberg School of Medicine
                  address:
                     name:Northwestern University Feinberg School of Medicine, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Francis Giles
            affiliation:
                  name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
                  address:
                     name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
                     type:PostalAddress
                  type:Organization
                  name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
                  address:
                     name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
                     type:PostalAddress
                  type:Organization
                  name:Northwestern University Feinberg School of Medicine
                  address:
                     name:Northwestern University Feinberg School of Medicine, Chicago, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal for ImmunoTherapy of Cancer
      issn:
         2051-1426
      volumeNumber:6
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
      address:
         name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
         type:PostalAddress
      name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
      address:
         name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
         type:PostalAddress
      name:Northwestern University Feinberg School of Medicine
      address:
         name:Northwestern University Feinberg School of Medicine, Chicago, USA
         type:PostalAddress
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
      address:
         name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
         type:PostalAddress
      name:Northwestern University Feinberg School of Medicine
      address:
         name:Northwestern University Feinberg School of Medicine, Chicago, USA
         type:PostalAddress
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
      address:
         name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
         type:PostalAddress
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
      address:
         name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
         type:PostalAddress
      name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
      address:
         name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
         type:PostalAddress
      name:Northwestern University Feinberg School of Medicine
      address:
         name:Northwestern University Feinberg School of Medicine, Chicago, USA
         type:PostalAddress
      name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
      address:
         name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
         type:PostalAddress
      name:Northwestern University Feinberg School of Medicine
      address:
         name:Northwestern University Feinberg School of Medicine, Chicago, USA
         type:PostalAddress
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
      address:
         name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
         type:PostalAddress
      name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
      address:
         name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
         type:PostalAddress
      name:Northwestern University Feinberg School of Medicine
      address:
         name:Northwestern University Feinberg School of Medicine, Chicago, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Young Kwang Chae
      affiliation:
            name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
            address:
               name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
               type:PostalAddress
            type:Organization
            name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
            address:
               name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
               type:PostalAddress
            type:Organization
            name:Northwestern University Feinberg School of Medicine
            address:
               name:Northwestern University Feinberg School of Medicine, Chicago, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Ayush Arya
      affiliation:
            name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
            address:
               name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Wade Iams
      affiliation:
            name:Northwestern University Feinberg School of Medicine
            address:
               name:Northwestern University Feinberg School of Medicine, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Marcelo R. Cruz
      affiliation:
            name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
            address:
               name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Sunandana Chandra
      affiliation:
            name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
            address:
               name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
               type:PostalAddress
            type:Organization
            name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
            address:
               name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
               type:PostalAddress
            type:Organization
            name:Northwestern University Feinberg School of Medicine
            address:
               name:Northwestern University Feinberg School of Medicine, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Jaehyuk Choi
      affiliation:
            name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
            address:
               name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
               type:PostalAddress
            type:Organization
            name:Northwestern University Feinberg School of Medicine
            address:
               name:Northwestern University Feinberg School of Medicine, Chicago, USA
               type:PostalAddress
            type:Organization
      name:Francis Giles
      affiliation:
            name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit
            address:
               name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
               type:PostalAddress
            type:Organization
            name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University
            address:
               name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
               type:PostalAddress
            type:Organization
            name:Northwestern University Feinberg School of Medicine
            address:
               name:Northwestern University Feinberg School of Medicine, Chicago, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
      name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
      name:Northwestern University Feinberg School of Medicine, Chicago, USA
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
      name:Northwestern University Feinberg School of Medicine, Chicago, USA
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
      name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
      name:Northwestern University Feinberg School of Medicine, Chicago, USA
      name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
      name:Northwestern University Feinberg School of Medicine, Chicago, USA
      name:Developmental Therapeutics Program of the Division of Hematology Oncology, Early Phase Clinical Trials Unit, Chicago, USA
      name:Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA
      name:Northwestern University Feinberg School of Medicine, Chicago, USA

External Links {🔗}(254)

• Revenue of https://www.springernature.com/gp/authors
• How much does https://link.springernature.com/home/ net monthly?
• Get to know https://order.springer.com/public/cart's earnings
• How much does https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research net monthly?
• Get to know http://clinicaltrials.gov's earnings
• What are the earnings of https://doi.org/10.1517%2F14712598.8.8.1151?
• What's the income generated by http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18613766 each month?
• Monthly income for http://scholar.google.com/scholar_lookup?&title=Approved%20monoclonal%20antibodies%20for%20cancer%20therapy&journal=Expert%20Opin%20Biol%20Ther&doi=10.1517%2F14712598.8.8.1151&volume=8&issue=8&pages=1151-1158&publication_year=2008&author=Boyiadzis%2CM&author=Foon%2CKA
• Monthly income for https://doi.org/10.1038%2Fnrc3236
• Income figures for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22437872
• Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Antibody%20therapy%20of%20cancer&journal=Nat%20Rev%20Cancer&doi=10.1038%2Fnrc3236&volume=12&issue=4&pages=278-287&publication_year=2012&author=Scott%2CAM&author=Wolchok%2CJD&author=Old%2CLJ
• What's the financial outcome of https://doi.org/10.1111%2Fj.1476-5381.2009.00190.x?
• What's the financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19459844?
• Explore the financials of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697811
• Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Therapeutic%20antibodies%3A%20successes%2C%20limitations%20and%20hopes%20for%20the%20future&journal=Br%20J%20Pharmacol&doi=10.1111%2Fj.1476-5381.2009.00190.x&volume=157&issue=2&pages=220-233&publication_year=2009&author=Chames%2CP&author=Van%20Regenmortel%2CM&author=Weiss%2CE&author=Baty%2CD
• How much cash flow does https://doi.org/10.4161/mabs.1.3.8292 have monthly?
• Explore the financials of https://doi.org/10.1016%2Fj.nbt.2011.03.021
• How much profit does http://scholar.google.com/scholar_lookup?&title=Antibodies%20in%20oncology&journal=New%20Biotechnol&doi=10.1016%2Fj.nbt.2011.03.021&volume=28&issue=5&pages=518-529&publication_year=2011&author=Pillay%2CV&author=Gan%2CHK&author=Scott%2CAM generate?
• What's the financial intake of https://doi.org/10.1073%2Fpnas.0915174107?
• Explore the financials of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20160101
• What's the total monthly financial gain of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2840093?
• How much does http://scholar.google.com/scholar_lookup?&title=PD-1%20and%20CTLA-4%20combination%20blockade%20expands%20infiltrating%20T%20cells%20and%20reduces%20regulatory%20T%20and%20myeloid%20cells%20within%20B16%20melanoma%20tumors&journal=Proc%20Natl%20Acad%20Sci&doi=10.1073%2Fpnas.0915174107&volume=107&issue=9&pages=4275-4280&publication_year=2010&author=Curran%2CMA&author=Montalvo%2CW&author=Yagita%2CH&author=Allison%2CJP pull in?
• How much does https://doi.org/10.1172%2FJCI80011 pull in monthly?
• How much cash flow does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26325035 have monthly?
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588282's financial summary
• How much does http://scholar.google.com/scholar_lookup?&title=Anti%E2%80%93PD-1%2FPD-L1%20therapy%20of%20human%20cancer%3A%20past%2C%20present%2C%20and%20future&journal=J%20Clin%20Invest&doi=10.1172%2FJCI80011&volume=125&issue=9&pages=3384-3391&publication_year=2015&author=Chen%2CL&author=Han%2CX rake in every month?
• How much does https://journals.lww.com/oncology-times/blog/fdaactionsandupdates/pages/post.aspx?PostID=116 make?
• How much does https://www.cancer.gov/publications/dictionaries rake in every month?
• How much does https://doi.org/10.1097%2FCOC.0000000000000239 pull in monthly?
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26558876 bring in?
• How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892769 gross monthly?
• What's the financial gain of http://scholar.google.com/scholar_lookup?&title=CTLA-4%20and%20PD-1%20pathways%3A%20similarities%2C%20differences%2C%20and%20implications%20of%20their%20inhibition&journal=Am%20J%20Clin%20Oncol&doi=10.1097%2FCOC.0000000000000239&volume=39&issue=1&pages=98-106&publication_year=2016&author=Buchbinder%2CEI&author=Desai%2CA?
• How much does https://doi.org/10.1016%2FS1074-7613%2802%2900362-X pull in?
• Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12196291
• What's the financial intake of http://scholar.google.com/scholar_lookup?&title=The%20interaction%20properties%20of%20costimulatory%20molecules%20revisited&journal=Immunity&doi=10.1016%2FS1074-7613%2802%2900362-X&volume=17&issue=2&pages=201-210&publication_year=2002&author=Collins%2CAV&author=Brodie%2CDW&author=Gilbert%2CRJ&author=Iaboni%2CA&author=Manso-Sancho%2CR&author=Walse%2CB&author=Stuart%2CDI&author=van%20der%20Merwe%2CPA&author=Davis%2CSJ?
• What are the earnings of https://doi.org/10.1146%2Fannurev.immunol.19.1.565?
• See how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11244047 makes per month
• How much profit does http://scholar.google.com/scholar_lookup?&title=CTLA-4-mediated%20inhibition%20in%20regulation%20of%20T%20cell%20responses%3A%20mechanisms%20and%20manipulation%20in%20tumor%20immunotherapy&journal=Annu%20Rev%20Immunol&doi=10.1146%2Fannurev.immunol.19.1.565&volume=19&issue=1&pages=565-594&publication_year=2001&author=Chambers%2CCA&author=Kuhns%2CMS&author=Egen%2CJG&author=Allison%2CJP generate?
• How much income is https://doi.org/10.1146%2Fannurev.immunol.26.021607.090331 earning monthly?
• What's the financial outcome of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18173375?
• http://scholar.google.com/scholar_lookup?&title=PD-1%20and%20its%20ligands%20in%20tolerance%20and%20immunity&journal=Annu%20Rev%20Immunol&doi=10.1146%2Fannurev.immunol.26.021607.090331&volume=26&pages=677-704&publication_year=2008&author=Keir%2CME&author=Butte%2CMJ&author=Freeman%2CGJ&author=Sharpe%2CAH's financial summary
• How much does https://doi.org/10.1038%2Fni0702-611 bring in each month?
• Find out how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12087419 earns monthly
• How much profit is http://scholar.google.com/scholar_lookup?&title=CTLA-4%3A%20new%20insights%20into%20its%20biological%20function%20and%20use%20in%20tumor%20immunotherapy&journal=Nat%20Immunol&doi=10.1038%2Fni0702-611&volume=3&issue=7&pages=611-618&publication_year=2002&author=Egen%2CJG&author=Kuhns%2CMS&author=Allison%2CJP making per month?
• What's the total monthly financial gain of https://doi.org/10.1128%2FMCB.25.21.9543-9553.2005?
• Discover the revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16227604
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1265804's financial summary
• What's http://scholar.google.com/scholar_lookup?&title=CTLA-4%20and%20PD-1%20receptors%20inhibit%20T-cell%20activation%20by%20distinct%20mechanisms&journal=Mol%20Cell%20Biol&doi=10.1128%2FMCB.25.21.9543-9553.2005&volume=25&issue=21&pages=9543-9553&publication_year=2005&author=Parry%2CRV&author=Chemnitz%2CJM&author=Frauwirth%2CKA&author=Lanfranco%2CAR&author=Braunstein%2CI&author=Kobayashi%2CSV&author=Linsley%2CPS&author=Thompson%2CCB&author=Riley%2CJL's gross income?
• How much does https://doi.org/10.4049%2Fjimmunol.164.10.5319 rake in every month?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10799894 net monthly?
• http://scholar.google.com/scholar_lookup?&title=Structural%20analysis%20of%20CTLA-4%20function%20in%20vivo&journal=J%20Immunol&doi=10.4049%2Fjimmunol.164.10.5319&volume=164&issue=10&pages=5319-5327&publication_year=2000&author=Masteller%2CEL&author=Chuang%2CE&author=Mullen%2CAC&author=Reiner%2CSL&author=Thompson%2CCB's financial summary
• What is the earnings of https://doi.org/10.1084%2Fjem.182.2.459?
• Financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7543139
• http://scholar.google.com/scholar_lookup?&title=CD28%20and%20CTLA-4%20have%20opposing%20effects%20on%20the%20response%20of%20T%20cells%20to%20stimulation&journal=J%20Exp%20Med&doi=10.1084%2Fjem.182.2.459&volume=182&issue=2&pages=459-465&publication_year=1995&author=Krummel%2CMF&author=Allison%2CJP's total income per month
• What's the financial outcome of https://doi.org/10.1016%2FS1074-7613%2800%2980480-X?
• What are the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8673700?
• What's the monthly money flow for http://scholar.google.com/scholar_lookup?&title=Intracellular%20trafficking%20of%20CTLA-4%20and%20focal%20localization%20towards%20sites%20of%20TCR%20engagement&journal=Immunity&doi=10.1016%2FS1074-7613%2800%2980480-X&volume=4&issue=6&pages=535-543&publication_year=1996&author=Linsley%2CPS&author=Bradshaw%2CJ&author=Greene%2CJ&author=Peach%2CR&author=Bennett%2CKL&author=Mittler%2CRS?
• How much does https://doi.org/10.1084%2Fjem.192.2.303 net monthly?
• What are the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10899917?
• What's the financial outcome of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193248?
• How much income is http://scholar.google.com/scholar_lookup?&title=Immunologic%20self-tolerance%20maintained%20by%20CD25%2B%20CD4%2B%20regulatory%20T%20cells%20constitutively%20expressing%20cytotoxic%20T%20lymphocyte%E2%80%93associated%20antigen%204&journal=J%20Exp%20Med&doi=10.1084%2Fjem.192.2.303&volume=192&issue=2&pages=303-310&publication_year=2000&author=Takahashi%2CT&author=Tagami%2CT&author=Yamazaki%2CS&author=Uede%2CT&author=Shimizu%2CJ&author=Sakaguchi%2CN&author=Mak%2CTW&author=Sakaguchi%2CS earning monthly?
• How much cash flow does https://doi.org/10.1002%2Fj.1460-2075.1992.tb05481.x have monthly?
• Check the income stats for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=1396582
• What's the financial intake of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC556898?
• What's the income of http://scholar.google.com/scholar_lookup?&title=Induced%20expression%20of%20PD-1%2C%20a%20novel%20member%20of%20the%20immunoglobulin%20gene%20superfamily%2C%20upon%20programmed%20cell%20death&journal=EMBO%20J&doi=10.1002%2Fj.1460-2075.1992.tb05481.x&volume=11&issue=11&publication_year=1992&author=Ishida%2CY&author=Agata%2CY&author=Shibahara%2CK&author=Honjo%2CT?
• How much income does https://doi.org/10.1038%2Fnri1349 have?
• What's the monthly income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15122199?
• How much does http://scholar.google.com/scholar_lookup?&title=Co-inhibitory%20molecules%20of%20the%20B7%E2%80%93CD28%20family%20in%20the%20control%20of%20T-cell%20immunity&journal=Nat%20Rev%20Immunol&doi=10.1038%2Fnri1349&volume=4&issue=5&pages=336-347&publication_year=2004&author=Chen%2CL earn?
• https://doi.org/10.1158%2F1078-0432.CCR-13-3271's revenue stream
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=24714771 generate?
• What's the financial gain of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4185001?
• How much does http://scholar.google.com/scholar_lookup?&title=Association%20of%20PD-1%2C%20PD-1%20ligands%2C%20and%20other%20features%20of%20the%20tumor%20immune%20microenvironment%20with%20response%20to%20anti%E2%80%93PD-1%20therapy&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-13-3271&volume=20&issue=19&pages=5064-5074&publication_year=2014&author=Taube%2CJM&author=Klein%2CA&author=Brahmer%2CJR&author=Xu%2CH&author=Pan%2CX&author=Kim%2CJH&author=Chen%2CL&author=Pardoll%2CDM&author=Topalian%2CSL&author=Anders%2CRA gross monthly?
• How much profit does https://doi.org/10.1084%2Fjem.20051776 generate?
• Income figures for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=16606670
• What is the earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118286?
• What's the financial intake of http://scholar.google.com/scholar_lookup?&title=Tissue%20expression%20of%20PD-L1%20mediates%20peripheral%20T%20cell%20tolerance&journal=J%20Exp%20Med&doi=10.1084%2Fjem.20051776&volume=203&issue=4&pages=883-895&publication_year=2006&author=Keir%2CME&author=Liang%2CSC&author=Guleria%2CI&author=Latchman%2CYE&author=Qipo%2CA&author=Albacker%2CLA&author=Koulmanda%2CM&author=Freeman%2CGJ&author=Sayegh%2CMH&author=Sharpe%2CAH?
• How much profit does https://doi.org/10.1084%2Fjem.193.7.839 generate?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11283156 pull in?
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193370's total income per month
• See how much http://scholar.google.com/scholar_lookup?&title=B7-DC%2C%20a%20new%20dendritic%20cell%20molecule%20with%20potent%20costimulatory%20properties%20for%20T%20cells&journal=J%20Exp%20Med&doi=10.1084%2Fjem.193.7.839&volume=193&issue=7&pages=839-846&publication_year=2001&author=Tseng%2CS-Y&author=Otsuji%2CM&author=Gorski%2CK&author=Huang%2CX&author=Slansky%2CJE&author=Pai%2CSI&author=Shalabi%2CA&author=Shin%2CT&author=Pardoll%2CDM&author=Tsuchiya%2CH makes per month
• How much income is https://doi.org/10.4161%2Fonci.21335 earning monthly?
• How much does http://scholar.google.com/scholar_lookup?&title=Targeting%20PD-1%2FPD-L1%20interactions%20for%20cancer%20immunotherapy&journal=Oncoimmunol&doi=10.4161%2Fonci.21335&volume=1&issue=8&pages=1223-1225&publication_year=2012&author=Zitvogel%2CL&author=Kroemer%2CG rake in every month?
• Explore the financials of https://doi.org/10.1038%2Fnm730
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12091876's financial summary
• http://scholar.google.com/scholar_lookup?&title=Tumor-associated%20B7-H1%20promotes%20T-cell%20apoptosis%3A%20a%20potential%20mechanism%20of%20immune%20evasion&journal=Nat%20Med&doi=10.1038%2Fnm730&volume=8&issue=8&pages=793-800&publication_year=2002&author=Dong%2CH&author=Strome%2CSE&author=Salomao%2CDR&author=Tamura%2CH&author=Hirano%2CF&author=Flies%2CDB&author=Roche%2CPC&author=Lu%2CJ&author=Zhu%2CG&author=Tamada%2CK's financial summary
• How much money does https://doi.org/10.1073%2Fpnas.192461099 make?
• See how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12218188 makes per month
• Financial intake of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC129438
• Monthly income for http://scholar.google.com/scholar_lookup?&title=Involvement%20of%20PD-L1%20on%20tumor%20cells%20in%20the%20escape%20from%20host%20immune%20system%20and%20tumor%20immunotherapy%20by%20PD-L1%20blockade&journal=Proc%20Natl%20Acad%20Sci&doi=10.1073%2Fpnas.192461099&volume=99&issue=19&pages=12293-12297&publication_year=2002&author=Iwai%2CY&author=Ishida%2CM&author=Tanaka%2CY&author=Okazaki%2CT&author=Honjo%2CT&author=Minato%2CN
• Revenue of https://doi.org/10.1182%2Fblood-2006-11-060087
• Monthly income for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17289811
• What's the monthly income of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1896111?
• http://scholar.google.com/scholar_lookup?&title=Interaction%20between%20B7-H1%20and%20PD-1%20determines%20initiation%20and%20reversal%20of%20T-cell%20anergy&journal=Blood&doi=10.1182%2Fblood-2006-11-060087&volume=110&issue=1&pages=180-185&publication_year=2007&author=Tsushima%2CF&author=Yao%2CS&author=Shin%2CT&author=Flies%2CA&author=Flies%2CS&author=Xu%2CH&author=Tamada%2CK&author=Pardoll%2CDM&author=Chen%2CL's total income per month
• Explore the financials of https://doi.org/10.1158%2F0008-5472.CAN-12-4100
• What's the monthly money flow for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23633484?
• Learn how profitable http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686913 is on a monthly basis
• What's the revenue for http://scholar.google.com/scholar_lookup?&title=Dual%20blockade%20of%20PD-1%20and%20CTLA-4%20combined%20with%20tumor%20vaccine%20effectively%20restores%20T-cell%20rejection%20function%20in%20tumors&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-12-4100&volume=73&issue=12&pages=3591-3603&publication_year=2013&author=Duraiswamy%2CJ&author=Kaluza%2CKM&author=Freeman%2CGJ&author=Coukos%2CG?
• https://www.sciencedirect.com/science/article/pii/S1044579X0700034X's revenue stream
• How much revenue does https://doi.org/10.1038%2Fni1102-991 bring in?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12407406 bring in each month?
• How much money does http://scholar.google.com/scholar_lookup?&title=Cancer%20immunoediting%3A%20from%20immunosurveillance%20to%20tumor%20escape&journal=Nat%20Immunol&doi=10.1038%2Fni1102-991&volume=3&issue=11&pages=991-998&publication_year=2002&author=Dunn%2CGP&author=Bruce%2CAT&author=Ikeda%2CH&author=Old%2CLJ&author=Schreiber%2CRD make?
• How much revenue does https://doi.org/10.1172%2FJCI22685 produce monthly?
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15314682's financial summary
• How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC503781 earn?
• How much profit does http://scholar.google.com/scholar_lookup?&title=Immune%20recognition%20of%20self%20in%20immunity%20against%20cancer&journal=J%20Clin%20Invest&doi=10.1172%2FJCI22685&volume=114&issue=4&pages=468-471&publication_year=2004&author=Houghton%2CAN&author=Guevara-Pati%C3%B1o%2CJA make?
• How much profit is https://doi.org/10.1126%2Fscience.1203486 making per month?
• What's the financial outcome of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21436444?
• Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Cancer%20immunoediting%3A%20integrating%20immunity%E2%80%99s%20roles%20in%20cancer%20suppression%20and%20promotion&journal=Science&doi=10.1126%2Fscience.1203486&volume=331&issue=6024&pages=1565-1570&publication_year=2011&author=Schreiber%2CRD&author=Old%2CLJ&author=Smyth%2CMJ
• What's the monthly money flow for https://doi.org/10.1111%2Fj.1365-2567.2007.02587.x?
• What's the monthly money flow for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17386080?
• How much revenue does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2265921 bring in?
• How much money does http://scholar.google.com/scholar_lookup?&title=Cancer%20immunoediting%20from%20immune%20surveillance%20to%20immune%20escape&journal=Immunology&doi=10.1111%2Fj.1365-2567.2007.02587.x&volume=121&issue=1&pages=1-14&publication_year=2007&author=Kim%2CR&author=Emi%2CM&author=Tanabe%2CK generate?
• Learn how profitable https://doi.org/10.1158%2F1078-0432.CCR-14-1860 is on a monthly basis
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25501578's total income per month
• Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Immune%20escape%20mechanisms%20as%20a%20guide%20for%20cancer%20immunotherapy&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-14-1860&volume=21&issue=4&pages=687-692&publication_year=2015&author=Beatty%2CGL&author=Gladney%2CWL
• How much does https://doi.org/10.1093%2Fannonc%2Fmds262 bring in each month?
• How much cash flow does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22918927 have monthly?
• What's the revenue for http://scholar.google.com/scholar_lookup?&title=Combination%20immunotherapy%20approaches&journal=Ann%20Oncol&doi=10.1093%2Fannonc%2Fmds262&volume=23&issue=suppl%208&pages=viii41-viii46&publication_year=2012&author=Drake%2CC?
• Discover the revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21626032
• How much does http://scholar.google.com/scholar_lookup?&title=Camouflage%20and%20sabotage%3A%20tumor%20escape%20from%20the%20immune%20system&journal=Cancer%20Immunol%20Immunother&doi=10.1007%2Fs00262-011-1012-8&volume=60&issue=8&pages=1161-1171&publication_year=2011&author=Poschke%2CI&author=Mougiakakos%2CD&author=Kiessling%2CR gross monthly?
• How much revenue does https://doi.org/10.1172%2FJCI31405 produce monthly?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17476343 gross monthly?
• Earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1857231
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Immune%20surveillance%20of%20tumors&journal=J%20Clin%20Invest&doi=10.1172%2FJCI31405&volume=117&issue=5&pages=1137-1146&publication_year=2007&author=Swann%2CJB&author=Smyth%2CMJ bring in?
• Learn about the earnings of http://scholar.google.com/scholar_lookup?&title=Classification%20of%20current%20anticancer%20immunotherapies&journal=Oncotarget&volume=5&pages=12472-12508&publication_year=2015&author=Galluzzi%2CL&author=Vacchelli%2CE&author=Pedro%2CB-S&author=Buqu%C3%A9%2CA&author=Senovilla%2CL&author=Baracco%2CEE&author=Bloy%2CN&author=Castoldi%2CF&author=Abastado%2CJ-P&author=Agostinis%2CP
• What's the total monthly financial gain of https://doi.org/10.1056%2FNEJMoa1602252?
• Learn how profitable http://scholar.google.com/scholar_lookup?&title=Nivolumab%20for%20recurrent%20squamous-cell%20carcinoma%20of%20the%20head%20and%20neck&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1602252&volume=2016&issue=375&pages=1856-1867&publication_year=2016&author=Ferris%2CRL&author=Blumenschein%2CG&author=Fayette%2CJ&author=Guigay%2CJ&author=Colevas%2CAD&author=Licitra%2CL&author=Harrington%2CK&author=Kasper%2CS&author=Vokes%2CEE&author=Even%2CC is on a monthly basis
• How much money does https://doi.org/10.1200%2FJCO.2014.59.0703 make?
• Income figures for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25452452
• What's http://scholar.google.com/scholar_lookup?&title=Nivolumab%20for%20metastatic%20renal%20cell%20carcinoma%3A%20results%20of%20a%20randomized%20phase%20II%20trial&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2014.59.0703&volume=33&issue=13&pages=1430-1437&publication_year=2015&author=Motzer%2CRJ&author=Rini%2CBI&author=McDermott%2CDF&author=Redman%2CBG&author=Kuzel%2CTM&author=Harrison%2CMR&author=Vaishampayan%2CUN&author=Drabkin%2CHA&author=George%2CS&author=Logan%2CTF's gross income?
• What's the profit of https://doi.org/10.1056%2FNEJMoa1507643?
• Monthly income for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26412456
• Monthly income for http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705936
• Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Nivolumab%20versus%20docetaxel%20in%20advanced%20nonsquamous%20non%E2%80%93small-cell%20lung%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1507643&volume=373&issue=17&pages=1627-1639&publication_year=2015&author=Borghaei%2CH&author=Paz-Ares%2CL&author=Horn%2CL&author=Spigel%2CDR&author=Steins%2CM&author=Ready%2CNE&author=Chow%2CLQ&author=Vokes%2CEE&author=Felip%2CE&author=Holgado%2CE
• Income figures for https://doi.org/10.1056%2FNEJMoa1504627
• Learn about the earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26028407
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681400's total income per month
• Profit of http://scholar.google.com/scholar_lookup?&title=Nivolumab%20versus%20docetaxel%20in%20advanced%20squamous-cell%20non%E2%80%93small-cell%20lung%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1504627&volume=373&issue=2&pages=123-135&publication_year=2015&author=Brahmer%2CJ&author=Reckamp%2CKL&author=Baas%2CP&author=Crin%C3%B2%2CL&author=Eberhardt%2CWE&author=Poddubskaya%2CE&author=Antonia%2CS&author=Pluzanski%2CA&author=Vokes%2CEE&author=Holgado%2CE
• What's the financial intake of https://doi.org/10.1016%2FS1470-2045%2815%2970076-8?
• Learn how profitable http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25795410 is on a monthly basis
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Nivolumab%20versus%20chemotherapy%20in%20patients%20with%20advanced%20melanoma%20who%20progressed%20after%20anti-CTLA-4%20treatment%20%28CheckMate%20037%29%3A%20a%20randomised%2C%20controlled%2C%20open-label%2C%20phase%203%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2815%2970076-8&volume=16&issue=4&pages=375-384&publication_year=2015&author=Weber%2CJS&author=D%27Angelo%2CSP&author=Minor%2CD&author=Hodi%2CFS&author=Gutzmer%2CR&author=Neyns%2CB&author=Hoeller%2CC&author=Khushalani%2CNI&author=Miller%2CWH&author=Lao%2CCD generate?
• How much does https://doi.org/10.1056%2FNEJMoa1411087 generate monthly?
• How much money does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25482239 make?
• Get to know http://scholar.google.com/scholar_lookup?&title=PD-1%20blockade%20with%20nivolumab%20in%20relapsed%20or%20refractory%20Hodgkin%27s%20lymphoma&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1411087&volume=372&issue=4&pages=311-319&publication_year=2015&author=Ansell%2CSM&author=Lesokhin%2CAM&author=Borrello%2CI&author=Halwani%2CA&author=Scott%2CEC&author=Gutierrez%2CM&author=Schuster%2CSJ&author=Millenson%2CMM&author=Cattry%2CD&author=Freeman%2CGJ's earnings
• Profit of https://doi.org/10.1056%2FNEJMoa1501824
• What is the monthly revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25891174?
• See how much http://scholar.google.com/scholar_lookup?&title=Pembrolizumab%20for%20the%20treatment%20of%20non%E2%80%93small-cell%20lung%20Cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1501824&volume=372&issue=21&pages=2018-2028&publication_year=2015&author=Garon%2CEB&author=Rizvi%2CNA&author=Hui%2CR&author=Leighl%2CN&author=Balmanoukian%2CAS&author=Eder%2CJP&author=Patnaik%2CA&author=Aggarwal%2CC&author=Gubens%2CM&author=Horn%2CL makes per month
• How much does https://doi.org/10.1056%2FNEJMoa1503093 earn?
• What's the profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25891173?
• How much does http://scholar.google.com/scholar_lookup?&title=Pembrolizumab%20versus%20Ipilimumab%20in%20Advanced%20Melanoma&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1503093&volume=372&issue=26&pages=2521-2532&publication_year=2015&author=Robert%2CC&author=Schachter%2CJ&author=Long%2CGV&author=Arance%2CA&author=Grob%2CJJ&author=Mortier%2CL&author=Daud%2CA&author=Carlino%2CMS&author=McNeil%2CC&author=Lotem%2CM earn?
• How much money does http://scholar.google.com/scholar_lookup?&title=Antitumor%20activity%20and%20safety%20of%20pembrolizumab%20in%20patients%20%28pts%29%20with%20advanced%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck%20%28SCCHN%29%3A%20preliminary%20results%20from%20KEYNOTE-012%20expansion%20cohort&publication_year=2015&author=Seiwert%2CTY&author=Haddad%2CRI&author=Gupta%2CS&author=Mehra%2CR&author=Tahara%2CM&author=Berger%2CR&author=Lee%2CS-H&author=Burtness%2CB&author=Le%2CDT&author=Heath%2CK make?
• Learn how profitable https://doi.org/10.1016%2FS0140-6736%2816%2900561-4 is on a monthly basis
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26952546 generate monthly?
• How much cash flow does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480242 have monthly?
• Profit of http://scholar.google.com/scholar_lookup?&title=Atezolizumab%20in%20patients%20with%20locally%20advanced%20and%20metastatic%20urothelial%20carcinoma%20who%20have%20progressed%20following%20treatment%20with%20platinum-based%20chemotherapy%3A%20a%20single-arm%2C%20multicentre%2C%20phase%202%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2816%2900561-4&volume=387&issue=10031&pages=1909-1920&publication_year=2016&author=Rosenberg%2CJE&author=Hoffman-Censits%2CJ&author=Powles%2CT&author=van%20der%20Heijden%2CMS&author=Balar%2CAV&author=Necchi%2CA&author=Dawson%2CN&author=O%27Donnell%2CPH&author=Balmanoukian%2CA&author=Loriot%2CY
• Check the income stats for https://doi.org/10.1016%2FS0140-6736%2816%2900587-0
• What are the total earnings of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26970723?
• Monthly income for http://scholar.google.com/scholar_lookup?&title=Atezolizumab%20versus%20docetaxel%20for%20patients%20with%20previously%20treated%20non-small-cell%20lung%20cancer%20%28POPLAR%29%3A%20a%20multicentre%2C%20open-label%2C%20phase%202%20randomised%20controlled%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2816%2900587-0&volume=387&issue=10030&pages=1837-1846&publication_year=2016&author=Fehrenbacher%2CL&author=Spira%2CA&author=Ballinger%2CM&author=Kowanetz%2CM&author=Vansteenkiste%2CJ&author=Mazieres%2CJ&author=Park%2CK&author=Smith%2CD&author=Artal-Cortes%2CA&author=Lewanski%2CC
• Get to know what's the income of https://doi.org/10.1056%2FNEJMoa1302369
• Get to know http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23724867's earnings
• How much revenue does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698004 generate?
• What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Nivolumab%20plus%20ipilimumab%20in%20advanced%20melanoma&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1302369&volume=369&issue=2&pages=122-133&publication_year=2013&author=Wolchok%2CJD&author=Kluger%2CH&author=Callahan%2CMK&author=Postow%2CMA&author=Rizvi%2CNA&author=Lesokhin%2CAM&author=Segal%2CNH&author=Ariyan%2CCE&author=Gordon%2CR-A&author=Reed%2CK?
• Earnings of https://doi.org/10.1056%2FNEJMoa1504030
• See how much http://scholar.google.com/scholar_lookup?&title=Combined%20nivolumab%20and%20ipilimumab%20or%20monotherapy%20in%20untreated%20melanoma&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1504030&volume=2015&issue=373&pages=23-34&publication_year=2015&author=Larkin%2CJ&author=Chiarion-Sileni%2CV&author=Gonzalez%2CR&author=Grob%2CJJ&author=Cowey%2CCL&author=Lao%2CCD&author=Schadendorf%2CD&author=Dummer%2CR&author=Smylie%2CM&author=Rutkowski%2CP makes per month
• How much income does https://doi.org/10.1056%2FNEJMoa1709684 have?
• Financial intake of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28889792
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706778 income
• What is the earnings of http://scholar.google.com/scholar_lookup?&title=Overall%20survival%20with%20combined%20nivolumab%20and%20ipilimumab%20in%20advanced%20melanoma&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1709684&volume=377&issue=14&pages=1345-1356&publication_year=2017&author=Wolchok%2CJD&author=Chiarion-Sileni%2CV&author=Gonzalez%2CR&author=Rutkowski%2CP&author=Grob%2CJ-J&author=Cowey%2CCL&author=Lao%2CCD&author=Wagstaff%2CJ&author=Schadendorf%2CD&author=Ferrucci%2CPF?
• What's https://doi.org/10.1016%2FS1470-2045%2816%2930126-7's gross income?
• What is the monthly revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27269740?
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5474305's total income per month
• What is the earnings of http://scholar.google.com/scholar_lookup?&title=Sequential%20administration%20of%20nivolumab%20and%20ipilimumab%20with%20a%20planned%20switch%20in%20patients%20with%20advanced%20melanoma%20%28CheckMate%20064%29%3A%20an%20open-label%2C%20randomised%2C%20phase%202%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2816%2930126-7&volume=17&issue=7&pages=943-955&publication_year=2016&author=Weber%2CJS&author=Gibney%2CG&author=Sullivan%2CRJ&author=Sosman%2CJA&author=Slingluff%20Jr%2CCL&author=Lawrence%2CDP&author=Logan%2CTF&author=Schuchter%2CLM&author=Nair%2CS&author=Fecher%2CL?
• How much does https://doi.org/10.1016%2FS1470-2045%2817%2930428-X pull in monthly?
• What's the profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28729151?
• What are the earnings of http://scholar.google.com/scholar_lookup?&title=Standard-dose%20pembrolizumab%20in%20combination%20with%20reduced-dose%20ipilimumab%20for%20patients%20with%20advanced%20melanoma%20%28KEYNOTE-029%29%3A%20an%20open-label%2C%20phase%201b%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2817%2930428-X&volume=18&issue=9&pages=1202-1210&publication_year=2017&author=Long%2CGV&author=Atkinson%2CV&author=Cebon%2CJS&author=Jameson%2CMB&author=Fitzharris%2CBM&author=McNeil%2CCM&author=Hill%2CAG&author=Ribas%2CA&author=Atkins%2CMB&author=Thompson%2CJA?
• How much money does https://doi.org/10.1200%2FJCO.2016.34.15_suppl.3001 generate?
• Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=CheckMate%20012%3A%20safety%20and%20efficacy%20of%20first-line%20%281L%29%20nivolumab%20%28nivo%3B%20N%29%20and%20ipilimumab%20%28ipi%3B%20I%29%20in%20advanced%20%28adv%29%20NSCLC&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2016.34.15_suppl.3001&volume=34&issue=Suppl&publication_year=2016&author=Hellmann%2CM&author=Gettinger%2CS&author=Goldman%2CJ&author=Brahmer%2CJ&author=Borghaei%2CH&author=Chow%2CL&author=Ready%2CN&author=Gerber%2CD&author=Juergens%2CR&author=Shepherd%2CF
• How much does https://doi.org/10.1016%2FS1470-2045%2815%2900544-6 make?
• Income figures for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26858122
• How much cash flow does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500167 have monthly?
• http://scholar.google.com/scholar_lookup?&title=Safety%20and%20antitumour%20activity%20of%20durvalumab%20plus%20tremelimumab%20in%20non-small%20cell%20lung%20cancer%3A%20a%20multicentre%2C%20phase%201b%20study&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2815%2900544-6&volume=17&issue=3&pages=299-308&publication_year=2016&author=Antonia%2CS&author=Goldberg%2CSB&author=Balmanoukian%2CA&author=Chaft%2CJE&author=Sanborn%2CRE&author=Gupta%2CA&author=Narwal%2CR&author=Steele%2CK&author=Gu%2CY&author=Karakunnel%2CJJ's total income per month
• Discover the revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26380628
• What is the earnings of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570074?
• What is the earnings of http://scholar.google.com/scholar_lookup?&title=Combination%20immunotherapy%20superior%20to%20monotherapy%20in%20patients%20with%20melanoma&journal=Am%20Health%20Drug%20Benefits&volume=8&issue=Spec%20Issue&publication_year=2015&author=Doyle%2CC?
• https://doi.org/10.1056%2FNEJMoa1200690's financial summary
• Discover the revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22658127
• How much does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544539 pull in?
• What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Safety%2C%20activity%2C%20and%20immune%20correlates%20of%20anti%E2%80%93PD-1%20antibody%20in%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1200690&volume=366&issue=26&pages=2443-2454&publication_year=2012&author=Topalian%2CSL&author=Hodi%2CFS&author=Brahmer%2CJR&author=Gettinger%2CSN&author=Smith%2CDC&author=McDermott%2CDF&author=Powderly%2CJD&author=Carvajal%2CRD&author=Sosman%2CJA&author=Atkins%2CMB?
• What's the income generated by http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=26027431 each month?
• Financial intake of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5698905
• Learn how profitable http://scholar.google.com/scholar_lookup?&title=Combined%20Nivolumab%20and%20Ipilimumab%20or%20monotherapy%20in%20untreated%20melanoma&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1504030&volume=373&issue=1&pages=23-34&publication_year=2015&author=Larkin%2CJ&author=Chiarion-Sileni%2CV&author=Gonzalez%2CR&author=Grob%2CJJ&author=Cowey%2CCL&author=Lao%2CCD&author=Schadendorf%2CD&author=Dummer%2CR&author=Smylie%2CM&author=Rutkowski%2CP is on a monthly basis
• What's the financial outcome of https://doi.org/10.1200%2FJCO.2017.73.2289?
• Revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28841387
• What's the financial outcome of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791828?
• How much does http://scholar.google.com/scholar_lookup?&title=Efficacy%20and%20safety%20outcomes%20in%20patients%20with%20advanced%20melanoma%20who%20discontinued%20treatment%20with%20nivolumab%20and%20ipilimumab%20because%20of%20adverse%20events%3A%20a%20pooled%20analysis%20of%20randomized%20phase%20II%20and%20III%20trials&journal=J%20Clin%20Oncol&doi=10.1200%2FJCO.2017.73.2289&volume=35&issue=34&pages=3807-3814&publication_year=2017&author=Schadendorf%2CD&author=Wolchok%2CJD&author=Hodi%2CFS&author=Chiarion-Sileni%2CV&author=Gonzalez%2CR&author=Rutkowski%2CP&author=Grob%2CJ-J&author=Cowey%2CCL&author=Lao%2CCD&author=Chesney%2CJ make?
• Profit of https://doi.org/10.1016%2FS1470-2045%2816%2930098-5
• Check the income stats for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27269741
• How much does http://scholar.google.com/scholar_lookup?&title=Nivolumab%20alone%20and%20nivolumab%20plus%20ipilimumab%20in%20recurrent%20small-cell%20lung%20cancer%20%28CheckMate%20032%29%3A%20a%20multicentre%2C%20open-label%2C%20phase%201%2F2%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2816%2930098-5&volume=17&issue=7&pages=883-895&publication_year=2016&author=Antonia%2CSJ&author=L%C3%B3pez-Martin%2CJA&author=Bendell%2CJ&author=Ott%2CPA&author=Taylor%2CM&author=Eder%2CJP&author=J%C3%A4ger%2CD&author=Pietanza%2CMC&author=Le%2CDT&author=de%20Braud%2CF earn?
• How much profit does https://doi.org/10.1093%2Fjnci%2Fdju244 make?
• Revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=25265940
• How much money does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200059 make?
• What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Development%20of%20the%20National%20Cancer%20Institute%E2%80%99s%20patient-reported%20outcomes%20version%20of%20the%20common%20terminology%20criteria%20for%20adverse%20events%20%28PRO-CTCAE%29&journal=J%20Natl%20Cancer%20Inst&doi=10.1093%2Fjnci%2Fdju244&volume=106&issue=9&publication_year=2014&author=Basch%2CE&author=Reeve%2CBB&author=Mitchell%2CSA&author=Clauser%2CSB&author=Minasian%2CLM&author=Dueck%2CAC&author=Mendoza%2CTR&author=Hay%2CJ&author=Atkinson%2CTM&author=Abernethy%2CAP?
• How much does https://doi.org/10.1056%2FNEJMoa1606774 pull in?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27718847 rake in every month?
• How much does http://scholar.google.com/scholar_lookup?&title=Pembrolizumab%20versus%20chemotherapy%20for%20PD-L1%E2%80%93positive%20non%E2%80%93small-cell%20lung%20cancer&journal=N%20Engl%20J%20Med&doi=10.1056%2FNEJMoa1606774&volume=375&issue=19&pages=1823-1833&publication_year=2016&author=Reck%2CM&author=Rodr%C3%ADguez-Abreu%2CD&author=Robinson%2CAG&author=Hui%2CR&author=Cs%C5%91szi%2CT&author=F%C3%BCl%C3%B6p%2CA&author=Gottfried%2CM&author=Peled%2CN&author=Tafreshi%2CA&author=Cuffe%2CS rake in every month?
• What are the earnings of https://news.bms.com/press-release/bristolmyers/bristol-myers-squibb-announces-top-line-resultscheckmate-026-phase-3-stu?
• What's the income generated by http://scholar.google.com/scholar_lookup?&title=NSCLC%2C%20metastaticCheckMate%20026%3A%20a%20phase%203%20trial%20of%20nivolumab%20vs%20investigator%27s%20choice%20%28IC%29%20of%20platinum-based%20doublet%20chemotherapy%20%28PT-DC%29%20as%20first-line%20therapy%20for%20stage%20iv%2Frecurrent%20programmed%20death%20ligand%201%20%28PD-L1%29%E2%88%92%20positive%20NSCLC&journal=Ann%20Oncol&volume=27&issue=suppl%206&publication_year=2016&author=Socinski%2CM&author=Creelan%2CB&author=Horn%2CL&author=Reck%2CM&author=Paz-Ares%2CL&author=Steins%2CM&author=Felip%2CE&author=van%20den%20Heuvel%2CM&author=Ciuleanu%2CT&author=Badin%2CF each month?
• What's the financial gain of https://doi.org/10.1016%2FS1470-2045%2816%2900175-3?
• Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27157491
• http://scholar.google.com/scholar_lookup?&title=Pembrolizumab%20for%20patients%20with%20PD-L1-positive%20advanced%20gastric%20cancer%20%28KEYNOTE-012%29%3A%20a%20multicentre%2C%20open-label%2C%20phase%201b%20trial&journal=Lancet%20Oncol&doi=10.1016%2FS1470-2045%2816%2900175-3&volume=17&issue=6&pages=717-726&publication_year=2016&author=Muro%2CK&author=Chung%2CHC&author=Shankaran%2CV&author=Geva%2CR&author=Catenacci%2CD&author=Gupta%2CS&author=Eder%2CJP&author=Golan%2CT&author=Le%2CDT&author=Burtness%2CB's revenue stream
• How much does https://doi.org/10.1371%2Fjournal.pone.0189848 pull in?
• What's the revenue for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=29284010?
• Check the income stats for http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746232
• Revenue of http://scholar.google.com/scholar_lookup?&title=Safety%20and%20antitumor%20activity%20of%20the%20anti%E2%80%93PD-1%20antibody%20pembrolizumab%20in%20patients%20with%20advanced%20colorectal%20carcinoma&journal=PLoS%20One&doi=10.1371%2Fjournal.pone.0189848&volume=12&issue=12&publication_year=2017&author=O%E2%80%99Neil%2CBH&author=Wallmark%2CJM&author=Lorente%2CD&author=Elez%2CE&author=Raimbourg%2CJ&author=Gomez-Roca%2CC&author=Ejadi%2CS&author=Piha-Paul%2CSA&author=Stein%2CMN&author=Razak%2CARA
• Profit of https://doi.org/10.1016%2Fj.ejca.2017.01.009
• Get to know what's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=28214657
• What are the earnings of http://scholar.google.com/scholar_lookup?&title=Ipilimumab%20alone%20or%20in%20combination%20with%20nivolumab%20after%20progression%20on%20anti-PD-1%20therapy%20in%20advanced%20melanoma&journal=Eur%20J%20Cancer&doi=10.1016%2Fj.ejca.2017.01.009&volume=75&pages=47-55&publication_year=2017&author=Zimmer%2CL&author=Apuri%2CS&author=Eroglu%2CZ&author=Kottschade%2CLA&author=Forschner%2CA&author=Gutzmer%2CR&author=Schlaak%2CM&author=Heinzerling%2CL&author=Krackhardt%2CAM&author=Loquai%2CC?
• Get to know what's the income of https://doi.org/10.1002%2Fcpt.88
• What's http://scholar.google.com/scholar_lookup?&title=Innovative%20clinical%20trials%3A%20the%20LUNG-MAP%20study&journal=Clin%20Pharmacol%20Therapeutics&doi=10.1002%2Fcpt.88&volume=97&issue=5&pages=488-491&publication_year=2015&author=Steuer%2CC&author=Papadimitrakopoulou%2CV&author=Herbst%2CR&author=Redman%2CM&author=Hirsch%2CF&author=Mack%2CP&author=Ramalingam%2CS&author=Gandara%2CD's gross income?
• How much profit does https://citation-needed.springer.com/v2/references/10.1186/s40425-018-0349-3?format=refman&flavour=references make?
• What's the financial outcome of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Young%20Kwang%20Chae?
• Discover the revenue of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Young%20Kwang%20Chae%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• How much cash flow does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Ayush%20Arya have monthly?
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Ayush%20Arya%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en pull in monthly?
• Discover the revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Wade%20Iams
• What's the financial gain of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Wade%20Iams%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Find out how much https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Marcelo%20R.%20Cruz earns monthly
• Find out how much https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Marcelo%20R.%20Cruz%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en earns monthly
• What's the income generated by https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Sunandana%20Chandra each month?
• Monthly income for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Sunandana%20Chandra%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• Discover the revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Jaehyuk%20Choi
• Learn about the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Jaehyuk%20Choi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• What's the income generated by https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Francis%20Giles each month?
• What's the financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Francis%20Giles%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much does http://creativecommons.org/licenses/by/4.0/ pull in monthly?
• Profit of http://creativecommons.org/publicdomain/zero/1.0/
• How much money does https://s100.copyright.com/AppDispatchServlet?title=Current%20landscape%20and%20future%20of%20dual%20anti-CTLA4%20and%20PD-1%2FPD-L1%20blockade%20immunotherapy%20in%20cancer%3B%20lessons%20learned%20from%20clinical%20trials%20with%20melanoma%20and%20non-small%20cell%20lung%20cancer%20%28NSCLC%29&author=Young%20Kwang%20Chae%20et%20al&contentID=10.1186%2Fs40425-018-0349-3©right=The%20Author%28s%29.&publication=2051-1426&publicationDate=2018-05-16&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY%20%2B%20CC0 make?
• What's the monthly income of https://crossmark.crossref.org/dialog/?doi=10.1186/s40425-018-0349-3?
• What's the revenue for https://citation-needed.springer.com/v2/references/10.1186/s40425-018-0349-3?format=refman&flavour=citation?
• What's https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral's gross income?
• See how much https://www.springernature.com/gp/products makes per month
• How much money does https://www.springernature.com/gp/librarians make?
• Get to know what's the income of https://www.springernature.com/gp/societies
• Earnings of https://www.springernature.com/gp/partners
• What's the revenue for https://www.springer.com/?
• How much does https://www.nature.com/ rake in every month?
• What's the financial intake of https://www.biomedcentral.com/?
• What's the financial gain of https://www.palgrave.com/?
• How much does https://www.apress.com/ gross monthly?
• Income figures for https://www.springernature.com/gp/legal/ccpa
• How much does https://www.springernature.com/gp/info/accessibility rake in every month?
• Monthly income for https://support.springernature.com/en/support/home
• How much does https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations rake in every month?
• Income figures for https://www.springernature.com/

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Clipboard.js
• Pace
• Prism.js

CDN Services {📦}

• Crossref